Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCE985)

Drug Name
Phenazone Drug Info
Synonyms
antipyrine; Phenazone; 60-80-0; Antipyrin; Phenazon; Analgesine; Anodynine; Fenazone; Anodynin; Azophen; 2,3-Dimethyl-1-phenyl-5-pyrazolone; Antipirin; Phenozone; Methozin; Azophene; Phenylone; Pyrazophyl; Sedatine; Apirelina; Sedatin; Dimethyloxychinizin; Dimethyloxyquinazine; Phenazonum; Antipyrinum; Oxydimethylquinazine; Azophenum; Parodyne; Phenylon; Fenazona; 3-Antipyrine; Fenazon [Czech]; Auralgan; Fenazon; Fenazona [INN-Spanish]; Phenazone (pharmaceutical); 3H-Pyrazol-3-one, 1,2-dihydro-1,5-dimethyl-2-phenyl-; Oxydimethylquinizine
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2206
ChEBI ID
CHEBI:31225
CAS Number
CAS 60-80-0
TTD Drug ID
DMCE985
VARIDT Drug ID
DR00941
INTEDE Drug ID
DR0120

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 1 (COX-1) TT8NGED PGH1_HUMAN Inhibitor [1]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID Highest Status REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Investigative [2]
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Investigative [3]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Investigative [3]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Investigative [2]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Investigative [4]
Cytochrome P450 2A6 (CYP2A6) DEJVYAZ CP2A6_HUMAN Investigative [3]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Investigative [2]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Investigative [4]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Investigative [2]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Investigative [2]
RNA cytidine acetyltransferase (hALP) DEZV4AP NAT10_HUMAN Investigative [5]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 6.09 7.747 6.04 7.023
RNA cytidine acetyltransferase (hALP) DME NAT10 7.324 6.95 7.289 7.155
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 8.485 5.28 4.621 8.889
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 12.054 3.968 2.945 4.1
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 9.791 3.744 3.413 1.609
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 10.644 6.631 6.598 6.937
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 10.036 5.779 6.508 6.481
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.867 5.142 5.52 7.08
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 3.307 5.005 3.921 5.327
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 11.76 5.931 6.164 9.423
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 11.692 6.58 4.984 9.089
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Discovery agent
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 1 (COX-1) DTT PTGS1 3.97E-03 0.16 0.43
RNA cytidine acetyltransferase (hALP) DME NAT10 8.46E-03 -4.02E-02 -2.28E-01
Cytochrome P450 2C18 (CYP2C18) DME CYP2C18 5.67E-02 2.96E-03 1.50E-02
Cytochrome P450 2E1 (CYP2E1) DME CYP2E1 1.87E-04 -1.20E-01 -3.22E-01
Cytochrome P450 2C8 (CYP2C8) DME CYP2C8 1.82E-04 -1.35E-01 -5.84E-01
Cytochrome P450 2B6 (CYP2B6) DME CYP2B6 4.88E-01 -1.69E-05 -1.28E-04
Cytochrome P450 2A6 (CYP2A6) DME CYP2A6 2.02E-01 -2.49E-02 -1.81E-01
Cytochrome P450 1A2 (CYP1A2) DME CYP1A2 7.36E-01 1.62E-02 1.08E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 2.40E-01 -3.31E-02 -1.97E-01
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 7.30E-01 -1.91E-02 -1.41E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: a pharmacologist's perspective. Clin Exp Rheumatol. 2001 Nov-Dec;19(6 Suppl 25):S51-7.
2 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
3 Identification of the human hepatic cytochromes P450 involved in the in vitro oxidation of antipyrine. Drug Metab Dispos. 1996 Apr;24(4):487-94.
4 Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos. 1997 Mar;25(3):390-3.
5 Evaluation of the influence of diabetes mellitus on antipyrine metabolism and CYP1A2 and CYP2D6 activity. Pharmacotherapy. 2000 Feb;20(2):182-90.